ERYTHROCIN I.V. 1 G
ERYTHROMYCIN (ERYTHROMYCIN LACTOBIONATE) : 1 G · DIN 00682276 · AMDIPHARM LIMITED
Health Canada status: MARKETED
What is ERYTHROCIN I.V.?
ERYTHROCIN I.V. 1 G contains ERYTHROMYCIN (ERYTHROMYCIN LACTOBIONATE) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 00682276, held by AMDIPHARM LIMITED, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 12-May-2009. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ERYTHROCIN I.V. used for?
Treatment of infections (LRTI, skin/soft tissue, Legionnaires' disease) caused by susceptible strains when oral administration is not possible or higher serum levels are required.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00682276 |
|---|---|
| Brand name | ERYTHROCIN I.V. |
| Generic / active ingredient | ERYTHROMYCIN (ERYTHROMYCIN LACTOBIONATE) : 1 G |
| Manufacturer | AMDIPHARM LIMITED |
| Strength | 1 G |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | J01FA01 ERYTHROMYCIN |
| AHFS class | 08:12.12.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 12-May-2009 |
| Original market date | 1988-12-31 00:00:00 |
How is it administered?
15 to 20 mg/kg/day. Severe infections up to 4 g daily. Administer by continuous or intermittent IV infusion only. IV bolus/push is unacceptable. Dilute to 1-5 mg/mL.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Reconstituted stock: 96h refrigerated or 24h at 15-25°C. Final diluted solution: use within 8 hours.
How is it supplied?
Packages of 10 vials.
Contraindications
Hypersensitivity to macrolides; concurrent astemizole, terfenadine, cisapride, pimozide, ergotamine; history of QT prolongation/arrhythmia; electrolyte disturbances; use with lovastatin/simvastatin.
Warnings and precautions
QT prolongation and risk of Torsades de Pointes. Clostridium difficile-associated disease (CDAD). Infantile hypertrophic pyloric stenosis (IHPS) risk in infants. Hepatic dysfunction.
Is ERYTHROMYCIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by PHARMA STULLN INC. (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01FA01 ERYTHROMYCIN. 2 of 47 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ERYTHROCIN I.V. | 500 MG | POWDER FOR SOLUTION | AMDIPHARM LIMITED | MARKETED | DIN 00682268 |
| ALTI-ERYTHROMYCIN TAB 250MG USP | 250 MG | TABLET (ENTERIC-COATED) | ALTIMED PHARMA INC. | CANCELLED POST MARKET | DIN 00640263 |
| EES 600 TABLETS 600MG | 600 MG | TABLET | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00583782 |
| EES-200 | 40 MG | POWDER FOR SUSPENSION | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00000299 |
| EES-200 CHEWABLE TBS (ERYPED) | 200 MG | TABLET | ABBOTT LABORATORIES, LIMITED | CANCELLED POST MARKET | DIN 00000604 |
| EES-400 | 400 MG / 5 ML | POWDER FOR SUSPENSION | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00453617 |
| EMYCIN ECT 250MG | 250 MG | TABLET (ENTERIC-COATED) | THE UPJOHN COMPANY OF CANADA | CANCELLED POST MARKET | DIN 00030899 |
| ERYBID | 500 MG | TABLET | AMDIPHARM LIMITED | CANCELLED POST MARKET | DIN 00893862 |
| ERYC DELAYED-RELEASE CAPSULES | 250 MG | CAPSULE (ENTERIC-COATED) | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00607142 |
| ERYC DELAYED-RELEASE CAPSULES | 333 MG | CAPSULE (ENTERIC-COATED) | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00873454 |
Who else supplies ERYTHROMYCIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ERYTHROMYCIN appears in 767 registered pack listings across 11 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.